Pinealon

Pinealon is a short synthetic peptide belonging to the class of peptide bioregulators developed in Russia by Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology ^[1][5]. Chemically it is the tripeptide Glu-Asp-Arg, commonly abbreviated EDR after the single-letter codes of its three amino acids (glutamic acid, aspartic acid, arginine) ^[1][3]. It is one of a family of ultrashort peptides, alongside relatives such as epitalon, vesugen, and cortagen, that are marketed as targeted regulators of specific tissues; pinealon is associated with the brain and central nervous system and is often described in supplement form as a pineal or neuronal peptide ^[2][5].

Research on pinealon has focused on neuroprotection and healthy aging. In animal models of hypobaric and prenatal hypoxia, pinealon showed the most pronounced antihypoxic and neuroprotective effect among a group of short peptides, increasing the resistance of neurons to oxygen deprivation ^[2]. In cell-culture work the EDR peptide reduces neuronal apoptosis, stimulates antioxidant enzyme activity, and, in a model of neuronal aging built from reprogrammed human fibroblasts, lowered oxidative DNA damage while promoting the branching of dendrites ^[1][3]. A substantial body of this literature examines the peptide's relevance to Alzheimer's disease and other age-related cognitive decline ^[1][6][7].

Much of the evidence base comes from the Khavinson research group and is preclinical or in vitro, with a smaller number of small human studies; one clinical report applied pinealon together with the peptide vesugen in older adults with organic brain syndrome and chronic polymorbidity, describing improvements in central nervous system activity and markers of biological age ^[4][5]. Pinealon is not an approved pharmaceutical in Western countries and is sold as a dietary supplement or research peptide, typically as a capsule or a powder for oral or injectable use under the Khavinson peptide bioregulator brands ^[4][5]. Its regulatory status, like that of the broader short-peptide category, remains outside mainstream drug approval frameworks ^[5].

Pinealon reads clean in the preclinical and Russian clinical record; short bioregulator peptides like this come across as low toxicity and well tolerated, without the immune or hormonal baggage of bigger peptides. In pigs, daily dosing at up to a thousand times the therapeutic range for six months left organs and blood work unremarkable, which is reassuring. Being honest though, the solid human evidence is thin and largely from one research lineage (Khavinson's group), so there is no established long term safety picture beyond that, and it is sold as an unscheduled research peptide, not an approved medicine. Self experiment reports mention only minor stuff; mild injection site irritation, an occasional headache, some fatigue, and at higher doses a little sleepiness, lower blood sugar, or a mood dip. Sensible to keep it to short courses and treat it as exploratory.

Pinealon is a synthetic tripeptide (Glu-Asp-Arg), also called the EDR peptide, from the family of short peptide bioregulators developed in Russia by Professor Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. This research program, which grew out of Soviet-era work on organ-derived peptide extracts beginning in the 1970s and 1980s, sought ultrashort peptides that could regulate gene expression and counter age-related decline. Pinealon was designed specifically to support the brain and target age-related cognitive impairment. Much of its published evidence comes from the developers' own laboratory and animal studies, with limited large-scale independent clinical validation to date.

Pinealon is one of the better-known members of the Khavinson short-peptide class and is discussed positively as a neuroprotective geroprotector for memory and healthy brain aging. Laboratory work is genuinely intriguing: the peptide has protected neurons from hypoxia and oxidative stress, supported dendrite growth in aged human-derived neurons, and appears to act through an unusual gene-regulatory mechanism rather than as a classical receptor drug. Enthusiasts appreciate this novel epigenetic angle and its clean safety impression. It is important to be candid that most of this evidence is preclinical and originates largely from the peptide's developers, and rigorous independent human trials quantifying its benefits are still lacking.